Table 1 Patient demographics and baseline characteristics
Variable | CET (n=100) | BEV (n=104) | P-value |
|---|---|---|---|
Age at onset (years) | 64.2±9.5 | 64.5±8.7 | 0.231 |
CRC locationa, n (%) | Â | Â | 0.331 |
 Left | 52 (52.0) | 47 (45.2) |  |
 Right | 48 (48.0) | 57 (54.8) |  |
Metastatic sites, n (%) | Â | Â | 0.848 |
 Intra-abdominal | 25 (25.0) | 27 (26.0) |  |
 Lung | 14 (14.0) | 16 (15.4) |  |
 Bone | 22 (22.0) | 26 (25.0) |  |
 Live | 25 (25.0) | 17 (16.3) |  |
 Brain | 7 (7.0) | 9 (8.7) |  |
 Other | 11 (11.0) | 1413.5) |  |
Serum lactate dehydrogenase level, n (%) | Â | Â | 0.428 |
 Normalb | 33 (33.0) | 29 (27.9) |  |
 Above normal | 67 (67.0) | 75 (72.1) |  |
Portal vein invasion, n (%) | Â | Â | 0.733 |
 Yes | 67 (67.0) | 72 (69.2) |  |
 No | 33 (33.0) | 32 (30.8) |  |
Duration of treatment (months) | 27.2±11.4 | 27.3±12.5 | 0.106 |
Hepatic encephalopathy, n (%) | 0 (0.0) | 0 (0) | 1.000 |
ECOG PS, n (%) | Â | Â | 0.860 |
 0 | 43 (43.0) | 46 (44.2) |  |
 1 | 57 (57.0) | 58 (55.8) |  |
Number of metastatic sites, n (%) | Â | Â | 0.454 |
 3 | 13 (13.0) | 20 (19.2) |  |
 > 3 | 72 (72.0) | 68 (65.4) |  |
 Unknown | 15 (15.0) | 16 (15.4) |  |